NCT03164213

Brief Summary

The purpose of this study is to investigate effects of tDCS stimulation in the left primary motor area followed by naming therapy to improve language functions in patients with aphasia in the sub-acute stage.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for not_applicable stroke

Timeline
Completed

Started May 2018

Typical duration for not_applicable stroke

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 24, 2017

Completed
29 days until next milestone

First Posted

Study publicly available on registry

May 23, 2017

Completed
11 months until next milestone

Study Start

First participant enrolled

May 1, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2020

Completed
Last Updated

March 14, 2018

Status Verified

March 1, 2018

Enrollment Period

1.7 years

First QC Date

April 24, 2017

Last Update Submit

March 13, 2018

Conditions

Keywords

tDCSaphasia

Outcome Measures

Primary Outcomes (1)

  • Change in "Shemesh" 100 nouns test (Biran and Friedmann 2005)

    language test

    baseline (before intervention), post intervention (on the third week from recruitment) and one month follow-up.

Secondary Outcomes (2)

  • Change in Western Aphasia Battery Hebrew

    baseline (before intervention), post intervention (on the third week from recruitment) and one month follow-up.

  • Change in Psycholinguistic Assessments of Language Processing in Aphasia

    baseline (before intervention), post intervention (on the third week from recruitment) and one month follow-up.

Study Arms (2)

Experimental tDCS

EXPERIMENTAL

TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).

Device: experimental: tDCS

sham tDCS

SHAM COMPARATOR

Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).

Device: sham tDCS

Interventions

The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.

Also known as: tDCS
Experimental tDCS
sham tDCSDEVICE

The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session. During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy.

sham tDCS

Eligibility Criteria

Age25 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients post stroke with right hemiplegia and aphasia with cognitive capacity to understand instructions and at the aphasia cut-of level defined by "SHEMESH" assessment

You may not qualify if:

  • unstable clinical state, craniotomy, epilepsy, heart pacer or lack of cooperation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

StrokeAphasia

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesSpeech DisordersLanguage DisordersCommunication DisordersNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Study Officials

  • Nachum Soroker, M.D.

    Loewenstein Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nachum Soroker, M.D

CONTACT

Corinne R Zarfati, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Head, Department of neurologic rehabilitation, Loewenstein

Study Record Dates

First Submitted

April 24, 2017

First Posted

May 23, 2017

Study Start

May 1, 2018

Primary Completion

December 30, 2019

Study Completion

April 30, 2020

Last Updated

March 14, 2018

Record last verified: 2018-03